Medical device company LeMaitre Vascular (NASDAQ: LMAT) will be reporting results this Thursday after the bell. Here’s what investors should know.
LeMaitre beat analysts’ revenue expectations by 2.6% last quarter, reporting revenues of $64.23 million, up 15% year on year. It was an exceptional quarter for the company, with a solid beat of analysts’ full-year EPS guidance estimates and an impressive beat of analysts’ organic revenue estimates.
Is LeMaitre a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting LeMaitre’s revenue to grow 13.7% year on year to $62.32 million, slowing from the 15.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.56 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. LeMaitre has missed Wall Street’s revenue estimates three times over the last two years.
Looking at LeMaitre’s peers in the healthcare equipment and supplies segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 22.9%, beating analysts’ expectations by 3%, and Integra LifeSciences reported revenues up 5.6%, falling short of estimates by 2.9%. Intuitive Surgical traded up 13.9% following the results while Integra LifeSciences was down 22.2%.
Read our full analysis of Intuitive Surgical’s results here and Integra LifeSciences’s results here.
Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices flat over the last month. LeMaitre’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $104.63 (compared to the current share price of $87.26).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
